Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. CRSP
stocks logo

CRSP

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
6.45M
+1146.72%
-1.438
-3.46%
12.99M
+2058.3%
-1.299
+28.62%
24.83M
-30.44%
-1.141
+159.31%
Estimates Revision
The market is revising Downward the revenue expectations for CRISPR Therapeutics AG (CRSP) for FY2025, with the revenue forecasts being adjusted by -14.69% over the past three months. During the same period, the stock price has changed by 46.35%.
Revenue Estimates for FY2025
Revise Downward
down Image
-14.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+10.28%
In Past 3 Month
Stock Price
Go Up
up Image
+46.35%
In Past 3 Month
21 Analyst Rating
up Image0
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.65 USD with a low forecast of 35.00 USD and a high forecast of 105.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
7 Hold
0 Sell
Moderate Buy
up Image0
Current: 56.800
sliders
Low
35.00
Averages
68.65
High
105.00
up Image0
Current: 56.800
sliders
Low
35.00
Averages
68.65
High
105.00
Clear Street
Bill Maughan
Buy
to
Hold
downgrade
$45
2025-06-27
Reason
Clear Street
Bill Maughan
Price Target
$45
2025-06-27
downgrade
Buy
to
Hold
Reason
Barclays
Equal Weight
downgrade
$56 -> $42
2025-05-09
Reason
Barclays
Price Target
$56 -> $42
2025-05-09
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Crispr Therapeutics to $42 from $56 and keeps an Equal Weight rating on the shares. The company's Q1 update highlighted promising initial CTX310 Phase 1 data, the analyst tells investors in a research note.
Needham
Gil Blum
Strong Buy
Reiterates
$84
2025-04-09
Reason
Needham
Gil Blum
Price Target
$84
2025-04-09
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Eric Schmidt
Hold
Reiterates
n/a
2025-02-19
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-02-19
Reiterates
Hold
Reason
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$89 → $82
2025-02-18
Reason
Citigroup
Yigal Nochomovitz
Price Target
$89 → $82
2025-02-18
Maintains
Strong Buy
Reason
Morgan Stanley
Terence Flynn
Sell
Maintains
$30 → $32
2025-02-14
Reason
Morgan Stanley
Terence Flynn
Price Target
$30 → $32
2025-02-14
Maintains
Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for CRISPR Therapeutics AG (CRSP.O) is -11.63, compared to its 5-year average forward P/E of -13.73. For a more detailed relative valuation and DCF analysis to assess CRISPR Therapeutics AG 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.73
Current PE
-11.63
Overvalued PE
10.28
Undervalued PE
-37.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.88
Current EV/EBITDA
-8.99
Overvalued EV/EBITDA
11.44
Undervalued EV/EBITDA
-25.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
318.76
Current PS
89.21
Overvalued PS
762.11
Undervalued PS
-124.58

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

CRSP News & Events

Events Timeline

(ET)
2025-06-27
08:45:01
Largest borrow rate increases among liquid names
select
2025-06-26 (ET)
2025-06-26
10:34:27
Crispr posts strong CTX310 data, says Chardan
select
2025-06-26
07:08:35
Crispr announces updates across in vivo cardiovascular disease progams
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-11Benzinga
CRISPR Stock Surges in Recent Weeks: What's Going On?
  • Recent Performance: CRISPR Therapeutics AG's stock has increased over 45% in the past month, driven by promising early-stage data on its experimental treatment CTX310, which effectively reduced triglycerides and LDL cholesterol without major safety concerns.

  • Analyst Ratings: Analysts have varied opinions on CRISPR's stock, with price targets ranging from $30 to $120; the consensus target is $70.50, while recent ratings include a mix of Buy, Hold, and Overweight recommendations.

Preview
8.0
07-10NASDAQ.COM
Interesting CRSP Put And Call Options For August 29th
  • Put Contract Details: The $59.00 put contract for CRISPR Therapeutics has a bid of $2.65, allowing investors to potentially buy shares at a lower cost basis of $56.35, with a 61% chance it may expire worthless, offering a 4.49% return on cash commitment.

  • Call Contract Insights: The $71.00 call contract offers a potential total return of 21.71% if the stock is called away, with a 69% chance of expiring worthless, providing a 3.33% additional return if retained, while the implied volatilities for the put and call contracts are 65% and 71%, respectively.

Preview
9.0
07-09Newsfilter
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
  • Cancer Statistics and Research Needs: Approximately 20 million people are diagnosed with cancer annually, leading to nearly 10 million deaths worldwide. The American Cancer Society projects that by 2050, annual diagnoses could reach 35 million, highlighting the urgent need for innovative therapies and ongoing research in oncology.

  • Calidi Biotherapeutics' Innovations: Calidi Biotherapeutics is developing a next-generation platform using engineered viruses to deliver genetic medicines directly to tumors, including hard-to-treat metastatic sites. Their lead candidate, CLD-401, aims to convert "cold" tumors into "hot" targets, enhancing immune response and potentially transforming cancer treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CRISPR Therapeutics AG (CRSP) stock price today?

The current price of CRSP is 56.8 USD — it has decreased -3.73 % in the last trading day.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s business?

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

arrow icon

What is the price predicton of CRSP Stock?

Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.65 USD with a low forecast of 35.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s revenue for the last quarter?

CRISPR Therapeutics AG revenue for the last quarter amounts to 865.00K USD, increased 71.63 % YoY.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s earnings per share (EPS) for the last quarter?

CRISPR Therapeutics AG. EPS for the last quarter amounts to -1.58 USD, increased 10.49 % YoY.

arrow icon

What changes have occurred in the market's expectations for CRISPR Therapeutics AG (CRSP)'s fundamentals?

The market is revising Downward the revenue expectations for CRISPR Therapeutics AG (CRSP) for FY2025, with the revenue forecasts being adjusted by -14.69% over the past three months. During the same period, the stock price has changed by 46.35%.
arrow icon

How many employees does CRISPR Therapeutics AG (CRSP). have?

CRISPR Therapeutics AG (CRSP) has 393 emplpoyees as of July 13 2025.

arrow icon

What is CRISPR Therapeutics AG (CRSP) market cap?

Today CRSP has the market capitalization of 4.91B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free